Article
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.
Oncogene - 1 Sept 2021
Wang Beike, Zhang Wei, Zhang Gao, Kwong Lawrence, Lu Hezhe, Tan Jiufeng, Sadek Norah, Xiao Min, Zhang Jie, Labrie Marilyne, Randell Sergio, Beroard Aurelie, Sugarman Eric, Rebecca Vito W, Wei Zhi, Lu Yiling, Mills Gordon B, Field Jeffrey, Villanueva Jessie, Xu Xiaowei, Herlyn Meenhard, Guo Wei
Abstract excerpt
Targeting MAPK pathway using a combination of BRAF and MEK inhibitors is an efficient strategy to treat melanoma harboring BRAF-mutation. The development of acquired resistance is inevitable due to the signaling pathway rewiring. Combining western blotting, immunohistochemistry, and reverse phase protein array (RPPA), we aim to understanding the role of the mTORC1 signaling pathway, a center node of intracellular...
Topics
- Humans
- Proto-Oncogene Proteins B-raf
- Melanoma
- Drug Resistance, Neoplasm
- Animals
- Mice
- Cell Line, Tumor
- Protein Kinase Inhibitors
- TOR Serine-Threonine Kinases